Day: November 29, 2021

Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer

CYNK-101 is an investigational genetically engineered natural killer (NK) cell therapy designed to synergize with antibody therapeutics Phase 1/2a clinical...

ENDRA Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology to Provide TAEUS for Patient Screening and Biomarker Measurement for Phase 2 Study

VGI’s Upcoming Phase 2 NAFLD-NASH study to incorporate ENDRA’s TAEUS technology to help drive trial efficiencies ANN ARBOR, Mich. &...

Cancer Patients May Get Faster and More Personalized Treatment as Result of Collaboration Between GE Healthcare, University of Cambridge and Addenbrooke’s Hospital

Teams plan to cooperate on the development of a machine learning-based solution, aiming to improve care for cancer patients by...

error: Content is protected !!